Dapagliflozin-Saxagliptin Combination - The Quest for Optimal Glycemic Control With Cardio-Renal Protection in Type 2 Diabetes Mellitus: An Expert Consensus in Indian Settings

被引：0

作者：

Ghosh, Sujoy ^{[10
]}

Wangnoo, Subhash K. ^{[1
]}

Chittawar, Sachin ^{[2
]}

Damodharan, Suresh ^{[3
]}

Kadam, Yogesh ^{[4
]}

Kalra, Pramila ^{[5
]}

Kumar, K. P. Suresh ^{[6
]}

Periyandavar, I. ^{[7
]}

Sharma, S. K. ^{[8
]}

Zargar, Abdul Hamid ^{[9
]}

机构：

[1] Manipal Hosp, Kolkata, W Bengal, India

[2] Indraprastha Apollo Hosp, New Delhi, India

[3] Gandhi Med Coll, Bhopal, Madhya Pradesh, India

[4] Harvey Specialty Clin, Coimbatore, Tamil Nadu, India

[5] Poona Diabet Ctr, Pune, Maharashtra, India

[6] Ramaiah Med Coll & Hosp, Dept Endocrinol, Bengaluru, Karnataka, India

[7] Kauvery Hosp, Chennai, Tamil Nadu, India

[8] Saroja Diabet Ctr, Chennai, Tamil Nadu, India

[9] Galaxy Specialty Ctr, Jaipur, Rajasthan, India

[10] Ctr Diabet & Endocrine Care, Srinagar, Jammu & Kashmir, India

来源：

JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 2024年 / 14卷 / 03期

关键词：

Dipeptidyl peptidase-4 inhibitor; Cardiovascular comor- bidities; Chronic kidney disease; Fixed-dose combination; Sodium- glucose cotransporter-2 inhibitor; Type 2 diabetes mellitus; ADD-ON THERAPY; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; REAL-WORLD EVIDENCE; ALL-CAUSE MORTALITY; DOUBLE-BLIND TRIAL; CARDIOVASCULAR OUTCOMES; HEART-FAILURE; PLUS DAPAGLIFLOZIN; EUROPEAN ASSOCIATION; TRIPLE THERAPY;

D O I：

10.14740/jem946

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The combination of dapagliflozin (DAPA; a sodium-glucose cotransporter-2 inhibitor (SGLT2i)) and saxagliptin (SAXA; a dipeptidyl peptidase-4 inhibitor (DPP4i)) added on to metformin targets multiple pathophysiological pathways and provides a synergistic effect on glycemic control. Notably, both DAPA and SAXA have demonstrated cardiovascular safety and shown to slow the progression of declining renal function in patients with type 2 diabetes mellitus (T2DM) having comorbid cardiovascular or renal diseases. Together, DAPA + SAXA has an acceptable tolerability profile, comparable with the individual agents and with a low propensity for hypoglycemia. The addition of DAPA + SAXA to metformin has been associated with low frequency of urinary tract and genital infections, attributed to the complementary effects of combining an SGLT2i and a DPP4i. This review compiles insights from a group of leading experts from India, summarizing concise clinical practice recommendations for the use of a fixed-dose combination of DAPA (10 mg) + SAXA (5 mg) in Indian patients with T2DM. The review encompasses available evidence and tion in the management of T2DM.

引用

页码：128 / 148

页数：21